Citations

Clear

52 citation(s) found for "Kim, Kyung Mo".

Beyond Doppler: Scalable AI Detection of LVOT Obstruction in HCM
Crystal, Owen , Farina, Juan M. , Scalia, Isabel G. , Ayoub, Chadi , Chollet, Laurève , Park, Hyung‐Bok , Kim, Kyung An , Arsanjani, Reza , Lester, Steven J., Crystal, Owen R , Villa Etchegoyen, Cecilia , Chollet, Laurève , Park, Hyung Bok , Kim, Kyung An , Arsanjani, Reza , Banerjee, Imon , Farina, Juan M , Scalia, Isabel G , Etchegoyen, Cecilia Villa , Lester, Steven J., Banerjee, Imon

Mayo Clinic

Circulation: Cardiovascular Imaging | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circimaging.126.019956 | PMID 42558066 Get It

BACKGROUND: Accurate assessment of left ventricular outflow tract (LVOT) gradients is critical for hypertrophic cardiomyopathy management, yet Doppler-based measurements are technically demanding and require expertise. The objective of this work was to develop a multi-view deep learning model capable of classifying LVOT obstruction (>20 mm Hg) using routine 2-dimensional echocardiographic windows without reliance on Doppler imaging. METHODS: We trained and externally validated a cross-attention-based video-to-video fusion framework that integrated EchoPrime-derived video representations from 3 standard transthoracic echocardiographic views to classify LVOT gradients. RESULTS: Training was performed on a derivation cohort (N=1833) from a tertiary care system in the United States, with model performance evaluated on an internally held-out test set (N=275) and a Korean external validation cohort (N=46). Single-view baselines showed limited discrimination (external area under the receiver operating curves, 0.47–0.70). Conversely, the domain-specific foundational model (EchoPrime) achieved superior single-view performance (area under the receiver operating curves, 0.75–0.80 internal; 0.79–0.83 external), highlighting the importance of echo-specific pretraining and temporal modeling. The proposed multi-view fusion further enhanced predictive performance, with the late fusion model reaching an area under the receiver operating curve of 0.84 on the external cohort with significant population-shift. CONCLUSIONS: These results suggest LVOT physiology is encoded in routine 2-dimensional imaging and can be leveraged for clinically relevant gradient classification without Doppler input. The proposed artificial intelligence-guided strategy demonstrates substantial cost savings compared with the screen-all approach. By integrating complementary spatial-temporal information across multiple views, our approach generalizes robustly across populations and may enable real-time decision support, extend LVOT assessment to portable or resource-limited settings, and complement Doppler-based evaluation for longitudinal hypertrophic cardiomyopathy management.
Single-electrode simultaneous detection of tonic dopamine and serotonin in vivo using an interleaved cyclic square wave voltammetry approach
Cho, Hyun-U., Hwang, Sangmun, Kwak, Youngjong , Kwon, Haeun , Jang, Jaehyun , Shin, Hojin, Lee, Kendall H., Jang, Dong Pyo, Kim, Kyung Min , Oh, Yoonbae , Lee, Kendall H., Jang, Dong Pyo

Mayo Clinic

Analytical Methods | July 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1039/d6ay00711b | PMID 42528485 Get It

We report an innovative interleaved voltammetric strategy to simultaneously quantify tonic levels of dopamine and serotonin in vivo using a single unmodified microelectrode, advancing our capability to monitor complex neurochemical interactions.
Beyond Doppler: Scalable AI Detection of LVOT Obstruction in HCM
Crystal, Owen , Farina, Juan Maria M, Scalia, Isabel G. , Ayoub, C A, Park, H B, Arsanjani, R A, Lester, Steven J, Banerjee, Imon, Arsanjani, Reza , Park, Hyung‐Bok , Arsanjani, Reza , Scalia, Isabel G , Park, Hyung Bok , Farina, Juan M. , Etchegoyen, Cecilia Villa , Chollet, Laurève , Kim, Kyung An , Lester, Steven J., Banerjee, Imon

Mayo Clinic

No container title available | April 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.17.26351151 Get It

Abstract Background Accurate assessment of left ventricular outflow tract (LVOT) gradients is critical for hypertrophic cardiomyopathy (HCM) management, yet Doppler-based measurements are technically demanding and require expertise. Objective To develop a multi-view deep learning model capable of classifying LVOT obstruction (> 20mmHg) using routine 2D echocardiographic windows without reliance on Doppler imaging. Methods We trained and externally validated a cross-attention-based video-to-video fusion framework that integrated EchoPrime-derived video representations from three standard transthoracic echocardiographic views to classify LVOT gradients. Results Training was performed on a derivation cohort (N = 1833) from a tertiary care system in the United States, with model performance evaluated on an internal held-out test set (N = 275) and a Korean external validation cohort (N = 46). Single-view baselines showed limited discrimination (external AUROCs 0.47–0.70). Conversely, domain-specific foundational model (EchoPrime) achieved superior single-view performance (AUROCs 0.75–0.80 internal; 0.79–0.83 external), highlighting the importance of echo-specific pretraining and temporal modeling. The proposed multi-view fusion further enhanced predictive performance, with the late fusion model reaching an AUROC of 0.84 on the external cohort with significant population-shift. Conclusions These results suggest LVOT physiology is encoded in routine 2D imaging and can be leveraged for clinically relevant gradient classification without Doppler input- proposed AI-guided strategy demonstrates substantial cost savings compared with the screen-all approach. By integrating complementary spatial-temporal information across multiple views, our approach generalizes robustly across populations and may enable real-time decision support, extend LVOT assessment to portable or resource-limited settings, and complement Doppler-based evaluation for longitudinal HCM management.
Neuroanatomical localization of faciobrachial dystonic seizures in LGI1 ‐antibody encephalitis
Ahn, Soo Hyun, Karaminiya, Maryam, Goh, Yihui , Ha, Woo‐Seok, Shin, Yoonhee, Jang, Yoonhyuk, Jung, Ki‐Young, Lee, Sang‐Kun, Kim, Kyung Min , Hong, Seung Bong , Irani, Sarosh, Lee, Soon‐Tae, Irani, Sarosh R. , Ha, Woo‐Seok , Lee, Sang-Kun , Lee, Soon-Tae , Irani, Sarosh R , Ha, Woo-Seok , Ahn, Soo Hyun , Jang, Yoonhyuk , Banks, Samantha A. , Jung, Ki‐Young , Chu, Kon , Lee, Soon‐Tae

Mayo Clinic

Epilepsia | March 13, 2026 | Volume: 67 | Issue: 5 | Pages: No page available

10.1002/epi.70197 | PMID 41823021 Get It

Abstract Faciobrachial dystonic seizures (FBDS), paroxysmal dizziness spells, and thermal sensory attacks are highly frequent and stereotypic phenomena experienced in leucine‐rich glioma inactivated 1 (LGI1)‐antibody encephalitis. This study aims to describe the electrophysiologic mechanism underlying these pathognomonic symptoms. LGI1‐antibody encephalitis patients with active symptoms were enrolled from two separate centers in South Korea and the United States. Patients were evaluated with simultaneous magnetoencephalography (306 channels) and electroencephalography. Regional alterations in neuronal excitability represented by interictal epileptiform discharges were present in the faciobrachial area of the motor cortex, insula, and somatosensory cortex, somatotopically aligned with each of the ictal semiologies observed in patients. FBDS and other LGI1‐antibody encephalitis‐specific spells localized to cortical regions neuroanatomically corresponding to ictal semiologies: the faciobrachial homunculus (FBDS), insular cortex (paroxysmal dizziness spells), and somatosensory cortex (thermal sensory attacks). Our findings support the ictal hypothesis underlying these unique phenomena.
Artificial Intelligence-Enabled Electrocardiography in Practice: A State-of-the-Art Review
Lee, Hak Seung , Croon, Philip, Lee, M, Poterucha, Timothy J. , Lin, Chin H., Son, J, Jeon, Ki Hyun , Tarabanis, Constantine , Lee, Seung‐Pyo , Kim, Kyung-Hee , Pandey, Ambarish , Kwon, J, Kim, Kyung‐Hee , Croon, Philip M , Lee, Min Sung , Poterucha, Timothy Joseph , Lin, Chin , Son, Jeong Min , Kwon, Joon-Myoung , Pandey, Ambarish

Mayo Clinic

Korean Circulation Journal | February 10, 2026 | Volume: 56 | Issue: 3 | Pages: 199

10.4070/kcj.2025.0486 | PMID 41866890 Get It

O21 Long-term efficacy and safety of filgotinib 200 mg in ulcerative colitis: 5-year interim data from SELECTIONLTE
Arnott, Ian , Feagan, Brian G. , Schreiber, S, Kim, Hyo Jong , Faes, Margaux , Mangili, Alexandra, Peyrin-Biroulet, Laurent, Matsuoka, Katsuyoshi , Rogler, Gerhard , Laharie, David , Vermeire, Séverine , Danese, Silvio , Loftus, Edward V. , Beales, Ian , Schreiber, Stefan , Rudolph, Christine , Peyrin‐Biroulet, Laurent

Mayo Clinic

Oral Presentations | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A15-A15

10.1136/gutjnl-2025-bsg.21 Get It

Adagrasib (Ada) + cetuximab (Cetux) for KRAS G12C -mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1.
Yaeger, Rona , Uboha, Nataliya V. , Sabari, Joshua K. , Peguero, Julio A. , Paulson, Andrew Scott , Jänne, Pasi A. , Pelster, Meredith , Kim, Amy Min Kyung, Hu, Nan , Ahmad, Harris A., Kopetz, Scott, Klempner, Samuel J. , Bekaii‐Saab, Tanios , Barve, Minal , Saltzman, Joel , Cruz‐Correa, Marcia , Kim, Amy Min Kyung, Ahmad, Harris A.

Mayo Clinic

Journal of Clinical Oncology | January 27, 2025 | Volume: 43 | Issue: 4_suppl | Pages: 131-131

10.1200/jco.2025.43.4_suppl.131 Get It

131 Background: KRAS G12C mutations occur in 3%–4% of CRC cases and are associated with poor prognosis. In the phase 1/2 KRYSTAL-1 study (NCT03785249), at a median follow-up of 11.9 months (mo), Ada (irreversible inhibitor of KRAS G12C ) in combination with Cetux (anti-EGFR antibody) demonstrated promising clinical activity (objective response rate [ORR] of 34% per blinded independent central review [BICR] and 43% per investigator [INV]) and was well tolerated in patients (pts) with previously treated KRAS G12C -mutated mCRC. Based on these findings, Ada + Cetux was granted accelerated approval in the United States for these pts. Here, we present longer-term follow-up analyses from this study. Methods: Adults with previously treated KRAS G12C -mutated mCRC and ECOG performance status of 0 or 1 were treated with Ada (600 mg BID) in combination with Cetux (400 mg/m 2 followed by 250 mg/m 2 QW or 500 mg/m 2 Q2W) until disease progression, unacceptable toxicity, withdrawal of consent, or death, in separate phase 1 and phase 2 cohorts. Primary endpoints were safety (phase 1) and ORR per BICR (phase 2). Secondary endpoints were duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety (phase 2). Results: A total of 94 pts received Ada + Cetux. The median number of prior lines of systemic therapy was 3 (range, 1–9); 23 pts (24%) had received ≥ 4 prior lines of systemic therapy. The most frequent sites of metastases at baseline were the lung (71%) and liver (64%). At a median follow-up of 20.4 mo, ORR per INV was 43% (95% CI 32–53) and all were partial responses; median DOR was 5.9 (95% CI 5.5–7.6) mo. Disease control rate per INV was 86% (95% CI 78–92). Median PFS per INV was 6.9 (95% CI 5.9–7.4) mo; 6- and 12-mo PFS rates were 61% and 19%, respectively. Median OS was 16.0 (95% CI 13.3–18.8) mo; 6- and 12-mo OS rates were 88% and 66%, respectively. Any-grade treatment-related adverse events (TRAEs) were reported in 100% of pts, 28% of which were grade 3/4. TRAEs led to discontinuation in 10% of pts. Efficacy analyses by BICR, subgroup analyses, and additional safety results will be presented. Conclusions: In heavily pretreated pts with KRAS G12C -mutated mCRC, Ada + Cetux continued to demonstrate clinically meaningful activity and tolerable safety with longer follow-up. These updated results are consistent with those from the primary analysis and constitute the longest duration of follow-up for dual KRAS G12C /EGFR blockade in this setting. Efficacy of second-line Ada + Cetux vs chemotherapy in KRAS G12C -mutated mCRC is being investigated in the phase 3 KRYSTAL-10 study (NCT04793958). Clinical trial information: NCT03785249 .
Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study
Feagan, Brian G., Matsuoka, Katsuyoshi , Rogler, Gerhard , Laharie, David , Vermeire, Séverine , Loftus, Edward V. , Beales, Ian , Schreiber, Stefan , Kim, Hyo Jong , Faes, Margaux , Haas, Angela de, Masior, Tomasz , Rudolph, Christine , Danese, Silvio , Loftus, Edward V , Beales, Ian , Schreiber, Stefan , Peyrin-Biroulet, Laurent , Vermeire, Séverine , Danese, Silvio , Peyrin‐Biroulet, Laurent , Matsuoka, K

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 1, 2024 | Volume: 60 | Issue: 5 | Pages: 563-584

10.1111/apt.18158 | PMID 39086130 Get It

SummaryBackgroundFilgotinib, an oral, once‐daily, Janus kinase 1 preferential inhibitor, is an approved treatment for moderately to severely active ulcerative colitis.AimsThe aim of this study is to assess the safety and efficacy of continued filgotinib therapy over ~4 years in the long‐term extension of the phase 2b/3 SELECTION trial (SELECTIONLTE; NCT02914535).MethodsIn this interim analysis of SELECTIONLTE, SELECTION completers (week 10 responders to filgotinib who completed the maintenance study) continued their assigned treatment (double‐blind filgotinib 200 mg [FIL200] or filgotinib 100 mg) and SELECTION week 10 non‐responders received open‐label FIL200. We assessed safety by adverse events (AEs), and efficacy by partial Mayo Clinic Score (pMCS), inflammatory biomarkers and health‐related quality of life (HRQoL). We compared safety and efficacy between achievers and non‐achievers of a multi‐component endpoint, comprehensive disease control (CDC), comprising symptomatic, endoscopic, inflammatory biomarker and HRQoL improvements.ResultsData for completers (n = 250) and non‐responders (n = 372) were reported for ≤202 weeks. AE occurrences were low and consistent with previous analyses. The as‐observed proportion of FIL200‐treated patients in pMCS, biomarker and HRQoL remission during SELECTIONLTE remained high among completers (week 144: 80.0%, 86.4% and 86.0%, respectively) and increased among non‐responders (week 192: 62.1%, 76.7% and 59.3%, respectively). Significantly higher proportions of CDC achievers at SELECTION week 58 achieved pMCS, IBDQ and corticosteroid‐free pMCS remission than non‐achievers, up to LTE week 96.ConclusionsFilgotinib induced and maintained symptomatic remission and improved HRQoL over 4 years. Safety results showed a proven long‐term benefit–risk profile. FIL200‐treated CDC achievers had better long‐term outcomes than non‐achievers.
Carbon Ion Radiotherapy: An Evidence-Based Review and Summary Recommendations of Clinical Outcomes for Skull-Base Chordomas and Chondrosarcomas
Seidensaal, Katharina , Iannalfi, Alberto , Koto, Masashi , Yang, Wan-Chin, Mahajan, Anita , Peterson, Jennifer , Koffler, Daniel , Vallow, Laura A., Rutenberg, Michael S. , Holtzman, Adam L. , Kim, Kyung Hwan , Ahmed, Safia K. , Trifiletti, Daniel M. , Hoppe, Bradford S.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1780150 Get It

P678 Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE
Officer, B G Feagan Senior Scientific, Kim, H J , Faes, Margaux , Masior, Tomasz , Rudolph, C, Matsuoka, Katsuyoshi , Rogler, Gerhard , Laharie, David , Vermeire, Séverine , Danese, Silvio , Loftus, Edward V. , Beales, Ian , Schreiber, Stefan , Peyrin‐Biroulet, Laurent

Mayo Clinic

Journal of Crohn's and Colitis | January 24, 2024 | Volume: 18 | Issue: Supplement_1 | Pages: i1278-i1279

10.1093/ecco-jcc/jjad212.0808 Get It

Abstract Background Filgotinib (FIL), an oral, once-daily, Janus kinase 1 inhibitor, was approved for Ulcerative Colitis (UC) treatment after the phase 2b/3 SELECTION trial (NCT02914522). In SELECTION, a greater proportion of FIL200 mg (FIL200)-treated than placebo-treated patients achieved comprehensive disease control (CDC), a stringent multi-component endpoint. We examined the long-term outcomes of achieving CDC in patients continuing on FIL200 in the ongoing long-term extension (LTE) study SELECTIONLTE (NCT02914535). Methods This interim analysis included adult patients with UC who completed SELECTION and received ≤144 weeks of FIL200 in the LTE (up to data cut-off 24/02/22). CDC (biomarker remission, endoscopic improvement, IBDQ remission and partial Mayo Clinic Score [pMCS] remission achieved concurrently) was assessed at SELECTION week 58 (LTE baseline [BL]). Mean pMCS and IBDQ score, use of corticosteroids (CS) and incidence of TEAEs and serious TEAEs in the LTE were compared between SELECTION CDC achievers and non-achievers. A mixed model for repeated measures was fitted on pMCS and IBDQ score, with CDC achiever status, study visit and the interaction between CDC achiever status and study visit as fixed effects; p values were nominal. Results We analysed 148 patients (CDC achievers, n=41; CDC non-achievers, n=107). Mean pMCS was stable in CDC achievers (0.44, LTE BL; 0.50, LTE week 144) and decreased in CDC non-achievers (1.49, LTE BL; 0.77, LTE week 144; Figure). Mean IBDQ score was stable in CDC achievers (204.05, LTE BL; 197.21, LTE week 144) and increased in CDC non-achievers (181.55, LTE BL; 196.37, LTE week 144; Figure). There was a significant beneficial effect of achieving CDC on pMCS and IBDQ score overall (pMCS: fixed effect estimate: −0.5542, p=0.0025; IBDQ score: fixed effect estimate: 13.1585, p=0.0042). There was a significant interaction between achieving CDC and study visit for IBDQ score (p=0.0183), with the benefit of achieving CDC lessening by week 144. Generally, a lower proportion of CDC achievers used CS than non-achievers; 2.4–7.3% of CDC achievers used CS vs 1.9–15.9% of CDC non-achievers. Incidence of TEAEs and serious TEAEs were stable over time and similar between CDC achievers and non-achievers. Conclusion Follow-up for ~3 years showed high levels of long-term benefit with continued FIL200 treatment. Achieving comprehensive disease control at the end of the randomized trial with FIL200 was associated with long-term efficacy, improved HRQoL and low overall use of CS. This may demonstrate the value of filgotinib-induced achievement of CDC in UC disease course. The safety profile of FIL200 was consistent between CDC achievers and non-achievers, suggesting an acceptable long-term benefit–risk profile.